Acute Porphyria Drug Database

J07AP03 - Typhoid, Purified Polysaccharide Antigen
Propably not porphyrinogenic
PNP

Rationale
Based on the pharmacokinetics of the typhoid, purified polysaccharide antigen vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Purified Vi capsular polysaccharide of Salmonella typhi
Therapeutic characteristics
The typhoid, purifies polysaccharide antigen vaccine is indicated for active immunization against typhoid fever caused by Salmonella enterica serovar typhi in adults and children 2 years of age or older. It is administered intramuscularly or subcutaneously as a single dose. Repeated vaccination every three years may be indicated for subjects at risk from typhoid fever.
Metabolism and pharmacokinetics
The typhoid polysaccharide vaccine is not metabolized by the cytochrome P450 system.
IPNet drug reports
Uneventful use reported in 2 patients with acute porphyria.

References

  1. Government bodies
  2. Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015). #1857
  3. Summary of Product Characteristics
  4. The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Typhim. (Last edition: January 2015). #1871

Similar drugs
Explore alternative drugs in similar therapeutic classes J07A / J07AP or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙